Edition:
India

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

7.76USD
2:29am IST
Change (% chg)

$-0.46 (-5.60%)
Prev Close
$8.22
Open
$8.25
Day's High
$8.25
Day's Low
$7.76
Volume
9,044
Avg. Vol
27,460
52-wk High
$21.59
52-wk Low
$7.22

Summary

Name Age Since Current Position

Charles Bisgaier

63 2014 Chairman of the Board, Chief Scientific Officer

Steven Gullans

64 2017 Interim President, Interim Chief Executive Officer, Director

Mina Sooch

49 2014 President, Chief Executive Officer, Director

Jeffrey Mathiesen

56 2015 Chief Financial Officer

Lee Golden

49 2016 Chief Medical Officer

Seth Reno

50 Chief Commercial Officer

P. Kent Hawryluk

48 2015 Independent Director

Kenneth Kousky

62 2015 Independent Director

Pedro Lichtinger

62 2015 Independent Director

Andrew Sassine

52 2015 Independent Director

Biographies

Name Description

Charles Bisgaier

Dr. Charles L. Bisgaier Ph.D., is Chairman of the Board, Chief Scientific Officer of the Company. Dr. Bisgaier was an Associate Research Fellow in the Department of Vascular and Cardiac Disease at Warner-Lambert/Parke-Davis. There he participated in the discovery and/or development of gemfibrozil (LOPID®), atorvastatin (LIPITOR®) and gemcabene (AKA CI-1027 and PD 72953). Subsequently, Dr. Bisgaier co-founded the first Esperion Therapeutics (1998- 2004), which was then acquired by Pfizer. At Pfizer he then served as the Senior Director of Pharmacology at the Esperion Division of Pfizer Global Research and Development. Notably, he was a major influence in the discovery, research and/or development of many small molecules with potential utility for metabolic syndrome including ETC-1002 (AKA ESP 55016) which was licensed by the new Esperion (NASDAQ: ESPR) from Pfizer, as well as HDL-therapy product candidates, such as ApoA-I Milano (ETC-216) which was also licensed by The Medicines Company (NASDAQ: MDCO) from Pfizer. After Pfizer, he served as a Company Director, Board Member and President of Pipex Pharmaceuticals (2006-2008, currently known as Synthetic Biologics, NYSE: SYN), a specialty pharmaceutical company focused on developing fibrotic and neurological disease therapies, that included a treatment for Relapsing Remitting Multiple Sclerosis. Both Pipex Pharmaceuticals and the first Esperion Therapeutics became public companies through a reverse-merger and an initial public offering (IPO), respectively during Dr. Bisgaier's tenure. He is also a co-founder of Michigan Life Therapeutics (predecessor to Gemphire) and Michigan Life Ventures. In addition, he is currently a Board member at Hygieia, Inc., a company that has developed a novel handheld medical device to assist diabetics to determine appropriate dosage when self-administering insulin, and a Board member at BioSavita Inc., a company that has developed a novel platform technology for protein expression in yeast.

Steven Gullans

Dr. Steven Gullans, Ph.D., is Interim President, Interim Chief Executive Officer, Director of the Company. He has served as a member of our Board since April 2016. He is a Managing Director at Excel Venture Management, LLC (“Excel”), one of our greater than 5% stockholders. Excel is a Boston-based venture capital firm which he co-founded and where he has been employed since February 2008. At Excel, he focuses on investing in life science technology companies with a particular interest in disruptive platforms that can impact multiple industries. Prior to Excel, Dr. Gullans co-founded RxGen, Inc., a pharmaceutical services company where he served as chief executive officer from January 2004 to February 2008. Dr. Gullans is currently a director at Cleveland HeartLab, Inc., a cardiovascular diagnostics company that spun out of the Cleveland Clinic; Molecular Templates, Inc., a clinical stage biotechnology company; N-of-One, Inc., an oncology diagnostics company; and Orionis Biosciences LLC, a drug development company. He was previously a board member of Activate Networks, Inc. which was acquired by Decision Resource Group; BioTrove, Inc. which was acquired by Life Technologies Corporation; Biocius Life Sciences, Inc. which was acquired by Agilent Technologies Inc.; nanoMR Inc. which was acquired by DNA Electronics Ltd; and Tetraphase Pharmaceuticals, Inc. which went public in 2013. Previously Dr. Gullans was a faculty member at Harvard Medical School and Brigham and Women’s Hospital for almost 20 years. Dr. Gullans holds a B.S. from Union College and a Ph.D. from Duke University. He is a Fellow of the American Heart Association and the American Association for the Advancement of Science.

Mina Sooch

Ms. Mina Patel Soochis is President, Chief Executive Officer, Director of the Company. Prior to joining Gemphire Therapeutics, she served from 2012 to 2014 as the CEO of ProNAi (NASDAQ:DNAI), a clinical-stage oncology company, and a board director from its founding in 2004 through 2014. At ProNAi, Ms. Sooch pioneered a new drug modality, DNAi, led the execution of Phase I and II trials on PNT2258 (a novel bcl2 targeted drug candidate) and raised over $70M in Series C and D financing from top tier institutional investors. The last round of $60M was the largest VC financing ever in Michigan’s history. Prior to her operating role, she has spent over a decade in life sciences venture capital through founding of Apjohn Ventures and also as EIR at Northcoast Technology Investors. As a VC, she led the sourcing and evaluation of deals across therapeutic areas, the investment terms and syndication, the governance, the follow-on financings totaling over $300M, and the exits of several life sciences companies. Also, she co-founded three start-ups (Afmedica, ProNAi, and Nephrion/Cytopherx). Notable exits from the Apjohn portfolio include the acquisition of ZyStor by BioMarin (NASDAQ:BMRN) in 2010, the acquisition of Afmedica by Angiotech Pharmaceuticals in 2005, and the product acquisition from Ikano by Upsher-Smith in 2010. Ms. Sooch has served on over 10 private, public, and VC industry boards including ProNAi, ZyStor, Asterand, Cytopherx, Svelte, Wolverine Venture Fund, and Michigan Venture Capital Association. Earlier in her career from 1993-2000, she served as global account manager at Monitor Group, a top tier global strategy consulting firm based in Boston. In 1995, she worked on the multi-billion Pharmacia & Upjohn merger. Mina received a MBA from Harvard Business School in 1993. She graduated summa cum laude and commencement speaker from Wayne State University in 1989 with a B.S. in Chemical Engineering.

Jeffrey Mathiesen

Mr. Jeffrey S. Mathiesen is Chief Financial Officer of the Company. Prior to joining Gemphire Therapeutics, he served as CFO of Sunshine Heart, Inc., leading the medical device company through its transition from the Australian capital markets to the U.S., which included a successful IPO and equity financings totaling approximately $100 million. Mr. Mathiesen has more than 20 years of experience as Chief Financial Officer (CFO) of publicly traded companies, including two successful initial public offerings (IPOs). His experience encompasses a variety of highly competitive, technology based industries in organizations with global reach and includes several M&A transactions, divestitures, organizational development and equity and debt financing. He began his career at Deloitte. Mr. Mathiesen also serves as Director and Audit Committee Chair of Sun BioPharma, Inc. a publicly traded biopharmaceutical company developing therapies for pancreatic diseases. Mr. Mathiesen graduated summa cum laude from the University of South Dakota with a B.S. degree in Accounting.

Lee Golden

Dr. Lee Golden is Chief Medical Officer of the Company. Prior to joining us from July 2011 to October 2016, Dr. Golden was the Therapeutic Area Head for CV, Pulmonary and CNS at Mesoblast, Ltd., a global regenerative medicine company. He also served as Therapeutic Area Head for Cardiovascular and Blood Disorders at Eisai Inc., a global pharmaceutical company from November 2009 to July 2011. From January, 2005 to March, 2008 he served as the Senior Director, US Medical at Actelion Pharmaceuticals US, Inc., a global biotech company, and from October 2001 to January 2005 he was a Medical Director and Team Leader in the US Cardiovascular and Metabolic Group at Pfizer. He received a B.S. in Physiological Psychology from University of Michigan, Ann Arbor, MI and earned his M.D. degree from New York University School of Medicine.

Seth Reno

Mr. Seth Reno is Chief Commercial Officer of the Company. He has extensive experience in building commercial capabilities to successfully commercialize both small and large molecules across a range of therapeutic areas including the cardiovascular market. Prior to joining Gemphire, he spent five years at Medimmune building commercial teams and capabilities that focused on launching complex biologics such as Mylept and Lynparza with orphan designation status into rare disease markets. As Medimmune’s Head of Commercial Operations he was responsible for leading core business functions across: Sales Operations, Marketing Operations, Market Research, Fleet Services, Sales Training, Commercial Insight, Advanced Analytics and Forecasting. Mr. Reno spent ten years at AstraZenca across a number of roles in Sales, Commercial Operations, Managed Markets and Brand Team. He led the Commercial Insight’s team for the dyslipidemia franchise, most notably the successful launch of Crestor’s atherosclerosis indication. He also led the insight work for several mixed dyslipidemia fixed dose combinations in development with industry partners. Prior to Joining AstraZeneca in 2001, Mr. Reno Spent eleven years at Wyeth in commercial operations and sales account management successfully building B2B relationships across Federal, Trade, Military and Commercial accounts. Mr. Reno holds a B.S. in Human Resources from University of Delaware and a MBA from Strayer University.

P. Kent Hawryluk

Mr. P. Kent Hawryluk is Independent Director of the Company. He is the Co-Founder and has served as the Chief Business Officer of Avidity NanoMedicines LLC, a precision nanomedicines company, since January 2013. He was also Co-Founder and served as the Chief Executive Officer of MB2 LLC, a clinical-stage company focused on diabetes and obesity, from May 2014 to March 2016. MB2 was acquired by Novo Nordisk in October 2015. Previously, in January 2006, Mr. Hawryluk co-founded Marcadia Biotech Inc., which was acquired by Roche Holding Ltd., where he served as Chief Business Officer and Vice President, Business Development from January 2006 to April 2011. He currently serves as partner of Twilight Venture Partners, LLC, a private seed and early-stage life science venture capital fund. He was a founding partner of JEGI Capital, LLC, a venture capital fund co-sponsored by GE Capital Corp. that launched in 2000. Mr. Hawryluk holds a B.A. from Princeton University, an M.B.A. from Kellogg School of Management at Northwestern University, and an M.S. degree in biology from Indiana University-Purdue University Indianapolis

Kenneth Kousky

Mr. Kenneth Kousky is Independent Director of the Company. Mr. Kousky has also served as the Chief Executive Officer of the Mid-Michigan Innovation Center, a privately funded, non-profit business incubator, since 2010. He has also served as the President and Chief Executive Officer of IP3, Inc., an information security consulting firm, since 2002. Also, Mr. Kousky is a founding member and has served as Executive Director of the Blue Water Angels Investment Network, a Michigan-based funding network that assists in private equity investments in early-stage tech startups, since 2008. In 1988, Mr. Kousky founded an IT services company, Wave Technologies International Inc., which he led through an initial public offering in 1994. In 1989, he established Washington University's graduate program in Telecommunication Management, and he has lectured at Saginaw Valley State University, Washington University and at the Wharton School of Business at the University of Pennsylvania. Mr. Kousky is a member of several corporate boards, including Michigan Sugar Corporation, RetroSense Therapeutics LLC and Foodjunky LLC. Mr. Kousky holds a B.A. in economics and urban studies from Washington University, and an M.S. in economics from University of Pennsylvania.

Pedro Lichtinger

Mr. Pedro Lichtinger is Independent Director of the Company. He was the President and Chief Executive Officer of Asterias Biotherapeutics, Inc., a publicly traded company with a focus on neurology and oncology from June 2014 to February 2016. Mr. Lichtinger served as President, Chief Executive Officer, and a director of Optimer Pharmaceuticals, Inc., from May 2010 to February 2013. Mr. Lichtinger previously served as an executive of Pfizer, Inc. from 1995 to 2009, including as President of Pfizer's Global Primary Care Unit from 2008 to 2009, Area President, Europe from 2006 to 2008, President, Global Animal Health from 1999 to 2006, and Regional President Europe Animal Health from 1995 to 1999. Before joining Pfizer, Mr. Lichtinger was an executive of Smith Kline Beecham Plc, last serving as Senior Vice-President Europe Animal Health from 1987 to 1995. Mr. Lichtinger serves as a director of Sanfer de Mexico, a leading Mexican pharmaceutical company. Mr. Lichtinger previously served as a director of BioTime, Inc. and Optimer Pharmaceuticals, Inc. Mr. Lichtinger holds an MBA degree from the Wharton School of Business and an engineering degree from the National University of Mexico.

Andrew Sassine

Mr. Andrew Sassine is Independent Director of the Company. Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, including as a Portfolio Manager for various funds from 2005 to December 2011. Mr. Sassine has also served on several boards of life science companies. Mr. Sassine currently serves on the board of directors of iCAD, Inc., a public cancer detection and radiation therapy solutions company and previously served on the boards of directors of FluoroPharma Medical, Inc., a public biopharmaceutical company, Acorn Energy, Inc., a public holding company focused on technology solutions for energy infrastructure asset management and CNS Response, Inc., a public psychiatric clinical decision support company. Mr. Sassine also serves on the board of directors of Freedom Meditech, Inc., a private medical device company, and Comhear Inc., a private digital audio software and device company, where he is also the chairman of the board of directors. Mr. Sassine serves on the Strategic Advisory Board of MD Revolution Inc., a private digital health service company. Mr. Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors since 2009 and served on the board of trustees at the Clarke Schools for Hearing and Speech from 2009 through 2014. Mr. Sassine holds a B.A. from the University of Iowa and an M.B.A. from the Wharton School at the University of Pennsylvania.

Basic Compensation